Bio-Gene Technology Ltd - Asset Resilience Ratio

Latest as of December 2025: 20.35%

Bio-Gene Technology Ltd (BGT) has an Asset Resilience Ratio of 20.35% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Bio-Gene Technology Ltd working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

AU$300.00K

≈ $212.27K USD Cash + Short-term Investments

Total Assets

AU$1.47 Million

≈ $1.04 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2025)

This chart shows how Bio-Gene Technology Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Bio-Gene Technology Ltd's balance sheet.

Liquid Assets Composition Over Time

This chart breaks down Bio-Gene Technology Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read debt load of Bio-Gene Technology Ltd for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$0.00	0%
Short-term Investments	AU$300.00K	20.35%
Total Liquid Assets	AU$300.00K	20.35%

Asset Resilience Insights

Good Liquidity Position: Bio-Gene Technology Ltd maintains a healthy 20.35% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Bio-Gene Technology Ltd Industry Peers by Asset Resilience Ratio

Compare Bio-Gene Technology Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Asymchem Laboratories Tian Jin Co Ltd SHE:002821	Biotechnology	5.07%
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	21.11%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	16.06%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Galapagos N.V. AS:GLPG	Biotechnology	86.45%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A SHG:688076	Biotechnology	0.91%

Annual Asset Resilience Ratio for Bio-Gene Technology Ltd (2017–2025)

The table below shows the annual Asset Resilience Ratio data for Bio-Gene Technology Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-06-30	23.26%	AU$500.00K ≈ $353.78K	AU$2.15 Million ≈ $1.52 Million	-24.22pp
2024-06-30	47.47%	AU$1.50 Million ≈ $1.06 Million	AU$3.16 Million ≈ $2.24 Million	+46.46pp
2022-06-30	1.02%	AU$74.20K ≈ $52.50K	AU$7.30 Million ≈ $5.17 Million	-77.64pp
2021-06-30	78.65%	AU$3.93 Million ≈ $2.78 Million	AU$5.00 Million ≈ $3.54 Million	-4.82pp
2018-06-30	83.48%	AU$6.40 Million ≈ $4.53 Million	AU$7.67 Million ≈ $5.42 Million	+62.30pp
2017-06-30	21.17%	AU$2.00 Million ≈ $1.42 Million	AU$9.45 Million ≈ $6.68 Million	--

pp = percentage points

About Bio-Gene Technology Ltd

AU:BGT Australia Biotechnology

Market Cap

$3.89 Million

AU$5.49 Million AUD

Market Cap Rank

#29158 Global

#1611 in Australia

Share Price

AU$0.02

Change (1 day)

+0.00%

52-Week Range

AU$0.02 - AU$0.04

All Time High

AU$0.34